L. Kinget

发表

Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study.

H. Wildiers, M. Baldewijns, P. Debruyne, 2021, Acta oncologica.

Trial watch: Dendritic cell (DC)-based immunotherapy for cancer

B. Neyns, Z. Berneman, J. Borst, 2022, Oncoimmunology.

Molecular Heterogeneity Between Paired Primary and Metastatic Lesions from Clear Cell Renal Cell Carcinoma

D. Lambrechts, J. Zucman‐Rossi, A. Verbiest, 2022, European Urology Open Science.

Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors

M. Baldewijns, H. Brems, P. Debruyne, 2021, Current oncology.

MicroRNAs Possibly Involved in the Development of Bone Metastasis in Clear-Cell Renal Cell Carcinoma

D. Lambrechts, J. Zucman‐Rossi, M. Baldewijns, 2021, Cancers.

MicroRNAs Targeting HIF-2α, VEGFR1 and/or VEGFR2 as Potential Predictive Biomarkers for VEGFR Tyrosine Kinase and HIF-2α Inhibitors in Metastatic Clear-Cell Renal Cell Carcinoma

J. Zucman‐Rossi, M. Baldewijns, G. Couchy, 2021, Cancers.

Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma

C. Verslype, B. Beuselinck, J. Dekervel, 2023, Cancers.

Trial watch: chemotherapy-induced immunogenic cell death in oncology

P. Vandenabeele, L. Zitvogel, O. Kepp, 2023, Oncoimmunology.

C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab.

M. Baldewijns, P. Debruyne, A. Verbiest, 2021, Urologic oncology.

Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications

D. Lambrechts, J. Zucman‐Rossi, M. Baldewijns, 2021, Acta oncologica.

Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials.

D. Lambrechts, J. Zucman‐Rossi, M. Baldewijns, 2021, Clinical genitourinary cancer.

First-line therapy for metastatic renal cell carcinoma with pancreatic metastases: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

C. Porta, T. Choueiri, N. Agarwal, 2022, Journal of Clinical Oncology.

A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma.

A. Verbiest, E. Roussel, B. Beuselinck, 2024, Nature medicine.